{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:07:31Z","timestamp":1790687251012,"version":"4.1.0"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T00:00:00Z","timestamp":1551312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0212948","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T13:47:52Z","timestamp":1551361672000},"page":"e0212948","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":29,"title":["Putting in harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. Experience from a tertiary hospital in Italy"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6149-0005","authenticated-orcid":true,"given":"Gina","family":"Gualano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8928-8183","authenticated-orcid":true,"given":"Paola","family":"Mencarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Musso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Mosti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Santangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Murachelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Cannas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Di Caro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assunta","family":"Navarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Goletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Girardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,2,28]]},"reference":[{"key":"ref1","year":"2017"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S1473-3099(18)30110-5","article-title":"Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies.","volume":"18","author":"S Tiberi","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"ref3","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1055\/s-0038-1661383","article-title":"Management of Multidrug-Resistant Tuberculosis.","volume":"39","author":"CL Daley","year":"2018","journal-title":"Semin Respir Crit Care Med"},{"issue":"3","key":"ref4","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00803-2016","article-title":"An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis","volume":"49","author":"ML Bastos","year":"2017","journal-title":"Eur Respir J"},{"issue":"49","key":"ref5","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2015.20.49.30087","article-title":"Tuberculosis treatment outcome in the European Union and European Economic Area: an analysis of surveillance data from 2002\u20132011","volume":"20","author":"B Karo","year":"2015","journal-title":"Euro Surveill"},{"issue":"5","key":"ref6","doi-asserted-by":"crossref","first-page":"e63057","DOI":"10.1371\/journal.pone.0063057","article-title":"Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa","volume":"8","author":"K Shean","year":"2013","journal-title":"PLoS One"},{"key":"ref7","year":"2014"},{"key":"ref8","year":"2016"},{"key":"ref9","year":"2014"},{"issue":"3","key":"ref10","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01643-2017","article-title":"The World Health Organization global aDSM database: generating evidence on the safety of new treatment regimens for drug-resistant tuberculosis","volume":"51","author":"CM Halleux","year":"2018","journal-title":"Eur Respir J"},{"issue":"3","key":"ref11","first-page":"275","article-title":"Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000\u20132004","volume":"14","author":"E Bloss","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.12659\/MSM.904682","article-title":"Adverse Events Associated with Treatment of Multidrug-Resistant Tuberculosis in China: An Ambispective Cohort Study","volume":"23","author":"Y Zhang","year":"2017","journal-title":"Med Sci Monit"},{"issue":"6","key":"ref13","doi-asserted-by":"crossref","first-page":"522","DOI":"10.4103\/0970-2113.217569","article-title":"Adverse drug reactions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: A four year retrospective study.","volume":"34","author":"AI Dela","year":"2017","journal-title":"Lung India"},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1097\/01.mjt.0000433951.09030.5a","article-title":"Adverse Events Associated With the Treatment of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-analysis.","volume":"23","author":"S Wu","year":"2016","journal-title":"Am J Ther"},{"issue":"11","key":"ref15","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.5588\/ijtld.17.0468","article-title":"The devil we know: is the use of injectable agents for the treatment of MDR-TB justified?","volume":"21","author":"A Reuter","year":"2017","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"ref16","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1183\/09031936.00022912","article-title":"Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis","volume":"40","author":"G Sotgiu","year":"2012","journal-title":"Eur Respir J"},{"issue":"10150","key":"ref17","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"392","author":"N Ahmad","year":"2018","journal-title":"Lancet"},{"issue":"7","key":"ref18","first-page":"648","article-title":"Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis","volume":"5","author":"JJ Furin","year":"2001","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5588\/ijtld.17.0498","article-title":"Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries","volume":"22","author":"A Tr\u00e9bucq","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"ref20","doi-asserted-by":"crossref","first-page":"e0120161","DOI":"10.1371\/journal.pone.0120161","article-title":"Doing no harm? Adverse events in a nation-wide cohort of patients with multidrug-resistant tuberculosis in Nigeria","volume":"10","author":"YK Avong","year":"2015","journal-title":"PLoS One"},{"issue":"9","key":"ref21","doi-asserted-by":"crossref","first-page":"996","DOI":"10.5588\/ijtld.17.0174","article-title":"Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease","volume":"21","author":"HY Yoon","year":"2017","journal-title":"Int J Tuberc Lung Dis"},{"issue":"12","key":"ref22","first-page":"1373","article-title":"Side effects associated with the treatment of multidrug-resistant tuberculosis","volume":"9","author":"T T\u00f6r\u00fcn","year":"2005","journal-title":"Int J Tuberc Lung Dis"},{"issue":"suppl 59","key":"ref23","article-title":"Side effect profile of 2nd line drugs in multi drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis","volume":"46","year":"2015","journal-title":"European Respiratory Journal Sep"},{"issue":"3","key":"ref24","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1473-3099(09)70041-6","article-title":"Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis.","volume":"9","author":"EW Orenstein","year":"2009","journal-title":"Lancet Infect Dis"},{"issue":"9979","key":"ref25","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/S0140-6736(15)60570-0","article-title":"WHO's new end TB strategy","volume":"385","author":"M Uplekar","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"ref26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5588\/pha.17.0013","article-title":"Unfavourable outcomes among patients with MDR-TB on the standard 24-month regimen in Maharashtra, India.","volume":"7","author":"SL Suryawanshi","year":"2017","journal-title":"Public Health Action"},{"issue":"5","key":"ref27","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1513\/AnnalsATS.201312-447OC","article-title":"Does Alcohol consumption during multidrug-resistant tuberculosis treatment affect outcome? A population-based study in Kerala, India","volume":"11","author":"K Duraisamy","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"ref28","year":"2014"},{"issue":"4","key":"ref29","first-page":"418","article-title":"Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance","volume":"62","author":"JP Cegielski","year":"2016","journal-title":"Clin Infect Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0212948","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T18:27:38Z","timestamp":1606588058000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0212948"}},"subtitle":[],"editor":[{"given":"Giuseppe Vittorio","family":"De Socio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,2,28]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0212948","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,28]]}}}